Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron's shares jumped 2.9% after Bank of America Securities upgraded its rating to 'Buy' and raised its price target to $860.00. Wall Street Zen upgraded Regeneron from a "hold" to a "buy" rating. Dupixent® (dupilumab) received approval in Japan for children aged 6 to 11 years with bronchial asthma. Regeneron presented new Th2-targeted programs at the 44th Annual J.P. Morgan Healthcare Conference. BMO Capital Markets boosted their price objective for Regeneron from $725.00 to $850.00. HSBC Global Res upgraded shares to a "strong-buy" rating. Regeneron reported its Q3 2025 earnings, with $11.83 EPS, surpassing the consensus estimate of $9.73. The stock experienced a 19% drop following mixed results from its Phase 3 trials for itepekimab. Morgan Stanley downgraded Regeneron to Equalweight with a $767 price target.

Information directly detailing demand seasonality for Regeneron Pharmaceuticals' products and services is not explicitly available in the provided search results. The search results indicate that seasonality analysis is available for REGN stock performance, which highlights recurring trends in stock price movements over specific months of the year. However, this stock seasonality does not directly translate to demand seasonality for the company's pharmaceutical products, which are typically driven by medical need, disease prevalence, and treatment cycles rather than calendar-based seasonal consumer trends.

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious diseases. It operates in the Healthcare sector, specifically in the Biotechnology industry, developing and marketing therapies for various conditions, including eye diseases, allergic and inflammatory diseases, cancer, and infectious diseases. Regeneron utilizes proprietary technology platforms like Trap and VelociSuite to identify therapeutic targets and generate fully human antibodies. Major products include EYLEA, Dupixent, Libtayo, Praluent, Evkeeza, Inmazeb, Kevzara, Arcalyst, Zaltrap and REGEN-COV.

Regeneron Pharmaceuticals' operational and financial activities are primarily concentrated in North America and Europe, which host 93.75% of its total entities. The company operates in the United States and the "Rest of the World." Regeneron has manufacturing units in the US and Ireland, and offices in 12 countries, with clinical trials underway in more than 50 countries. Its products are offered to healthcare providers in countries including the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan, and the UK.

Regeneron's brand reputation has been influenced by positive developments such as strong sales trends for key products and analyst upgrades, as well as setbacks like the mixed Phase 3 trial results for itepekimab for Chronic Obstructive Pulmonary Disease (COPD).

Regeneron Pharmaceuticals' shareholder base is primarily led by major institutional investors including The Vanguard Group, Inc., BlackRock Institutional Trust Company, N.A., and State Street Investment Management (US). Sanofi is the largest individual shareholder, holding 34.75% of the company's shares. Insiders have been net sellers recently. Institutional investors own 79% of Regeneron's shares, while retail investors and insiders own about 21%.